Skip to main content

Table 1 Epidemiological characteristics of the 4 included articles that presented longitudinal data

From: Leprosy detection rate in patients under immunosuppression for the treatment of dermatological, rheumatological, and gastroenterological diseases: a systematic review of the literature and meta-analysis

Author Autoimmune disease Medications Cases
(n)
Population
(n)
Screening time (years) Period detection rate/100,000 Detection rate/100,000/year
Lopes 2015 [35] Juvenile Lupus Erythematosus Prednisone, Hydroxychloroquine, Mycophenolate mofetil, Cyclophosphamide 1 312 32 320.50 10.02
Burmester 2016 [36] Rheumatoid Arthritis Tocilizumab 1 1262 2 79.20 39.62
Titton 2011 [23] Rheumatic Diseases; Anti-TNF and DMARDs 1 1037 0.83 96.43 116.18
Wallis RS 2005 [31] Not clear Infliximab 1 197,000 4 0.51 0.13
Total* 4 199,611 2.00
  1. n Number of patients, DMARDs Disease-modifying antirheumatic drugs, * Unadjusted values